|Bid||7.16 x 900|
|Ask||7.16 x 800|
|Day's Range||7.02 - 7.47|
|52 Week Range||6.41 - 26.79|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Santa Barbara, California-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Sientra, Inc. (NASDAQ:SIE...
The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants. Last month, the FDA issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease. The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190319:nPn7rwbQSa, dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...
, a plastic surgery product maker, were falling hard Wednesday after the company reported a wider-than-expected fourth-quarter loss. Sientra lost 87 cents a share in the quarter, wider than analysts' calls for a loss of 67 cents. The company has missed earnings estimates in the last four quarters.
Sientra (SIEN) delivered earnings and revenue surprises of -28.36% and 0.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Santa Barbara, California-based company said it had a loss of 86 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth inRead More...
“October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
In 2015 Jeff Nugent was appointed CEO of Sientra, Inc. (NASDAQ:SIEN). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look Read More...
Sientra (SIEN) delivered earnings and revenue surprises of -7.46% and 3.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Santa Barbara, California-based company said it had a loss of 72 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Hani Zeini, 54, was accused of letting the offering close on Sept. 23, 2015, despite having learned three days earlier from the chief executive of the company's sole supplier that European implant sales would be suspended because contamination had been detected in an audit of manufacturing procedures. Sientra's share price sank 52.9 percent on Sept. 24, 2015, to $9.70 from $20.58, after it disclosed that the U.K. Medicines and Healthcare Products Regulatory Agency had suspended the certificate needed for the supplier, Brazil's Silimed, to sell the implants. The SEC said Zeini had hid "damaging" details from "every other professional" working on his Santa Barbara, California-based company's 3 million share offering, including its chief financial officer, directors, lawyers, auditors and bankers, and tried to cover his tracks after it was done.